Tasigna, manufactured by pharma giant Novartis, is used in the treatment of certain types of leukemia. It was first approved for use in the United States in 2007, and shortly thereafter adverse event reports were beginning to rise. By 2011, as adverse event reports continued to grow, scientists began analyzing the drug and its potential side effects. Patients who suffered these adverse events should speak with a Tasigna claims attorney about seeking redress.
Researchers Associate Tasigna with Hardened Arteries
Table of Contents
That same year, a study published in the American Journal of Hematology associated Tasigna treatment with an increased risk of severe peripheral artery occlusion disease (PAOD). Scientists continued to analyze and evaluate Tasigna and published the results of a study in 2013 that also found an association between PAOD and Tasigna. In fact, researchers explained that of the 159 patients they studied, 26 percent of those on first-line Tasigna, and 35 percent of those on second-line Tasigna developed PAOD while only 6 percent of patients on alternative medications did.
Another study published the same year in the journal Blood also showed an association between Tasigna and PAOD. Researchers followed 34 patients for two years and determined that 26 percent of them developed PAOD and more than 17 percent had to be admitted to the hospital for extended treatment or for surgical intervention.
No Warnings for Severe Adverse Events
By this time, more than 4400 adverse event reports had been filed with the FDA, but still, Novartis chose not to warn of this association or recall it from the market. And while researchers were continuing to study the drug and its side effects, Novartis issued warnings about the association between PAOD and Tasigna elsewhere in the world, but not in the U.S.
In fact, Novartis issued warnings for Tasigna in brochures that were provided to doctors and patients and posted this information on the Health Canada website as well as the Novartis Canada website. These warnings allow patients and the medical community in Canada make informed decisions about the treatments and their care, including whether the risk of rapid developing atherosclerosis is worth the benefits of the drug.
Patients across the country are demanding to know why they did not receive adequate warnings about the association between treatment with Tasigna and the development of severe and potentially life-threatening side effects, and why they were denied the opportunity to make informed decisions.
Tasigna Injury Lawsuits Continue to Grow
Adverse event reports involving Tasigna have continued to grow since the drug was approved. In fact, the FDA reports it has received 13,645 adverse event reports, including 9563 injury reports and 2533 reports of death.
Now, patients who suffered heart attacks, strokes, and amputations are seeking justice and demanding answers. Lawsuits are being filed on behalf of these patients and their families for the injuries they suffered and the losses they incurred. For decades, we have been helping patients harmed by dangerous drugs and defective products get the justice and the compensation they deserve. If you or a leukemia patient you love was treated with Tasigna and then diagnosed with atherosclerosis or one of the dangerous complications of hardened arteries including heart attack, stroke, and amputations, contact us now to learn more about how we help and whether you are eligible to seek compensation.